Skip to main content
Top
Published in: Tumor Biology 5/2010

01-10-2010 | Research Article

Synthesis and structural characterization of the peptide epitope of the ovarian cancer biomarker CA125 (MUC16)

Authors: Zach T. Berman, Lee J. Moore, Kathleen E. Knudson, Rebecca J. Whelan

Published in: Tumor Biology | Issue 5/2010

Login to get access

Abstract

A highly conserved region of 21 amino acids flanked by cysteine residues, contained within a larger repeated domain, has been proposed to be the antibody-binding site in the ovarian cancer biomarker CA125 (MUC16). In this study solid-phase peptide synthesis with Fmoc protection chemistry was used to assemble a 21-mer peptide corresponding to the most frequently occurring antibody binding sequence in CA125. Potentially significant sequence variants were also synthesized. Peptide secondary structure was investigated using Fourier transform infrared spectroscopy, revealing the consensus sequence peptide to be largely unstructured at physiological pH whether the cysteine residues were reduced or were oxidized to form an intramolecular disulfide bond. Substitution of serine for proline at position 8 (P8S) results in β-sheet formation in peptides involved in intramolecular disulfide bonds. This β-sheet structure does not persist in peptides incapable of intramolecular disulfide bonding because of sequence nor in peptides treated with the reducing agent dithiothreitol. In CA125, P8S is predicted to occur in ∼25% of repeat domains, suggesting that this structural motif is a non-negligible contributor to overall structure and function. These findings suggest that future structural characterization efforts of CA125 should be especially mindful of the amino acid sequence and oxidation state of the protein.
Literature
2.
go back to reference Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–7.CrossRefPubMed Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–7.CrossRefPubMed
3.
go back to reference Bast RC, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7.CrossRefPubMed Bast RC, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7.CrossRefPubMed
4.
5.
go back to reference Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival—a review of the epidemiological literature. J Ovarian Res. 2009;2:13.CrossRefPubMed Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival—a review of the epidemiological literature. J Ovarian Res. 2009;2:13.CrossRefPubMed
6.
go back to reference Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15 suppl 3:274–81.CrossRefPubMed Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15 suppl 3:274–81.CrossRefPubMed
7.
go back to reference Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol. 2007;107:526–31.CrossRefPubMed Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol. 2007;107:526–31.CrossRefPubMed
8.
go back to reference O’Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumor Biol. 2001;22:348–66.CrossRef O’Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumor Biol. 2001;22:348–66.CrossRef
9.
go back to reference Yin BWT, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001;276:27371–5.CrossRefPubMed Yin BWT, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001;276:27371–5.CrossRefPubMed
10.
go back to reference O’Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumor Biol. 2002;23:154–69.CrossRef O’Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumor Biol. 2002;23:154–69.CrossRef
11.
go back to reference Yin BWT, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer. 2002;98:737–40.CrossRefPubMed Yin BWT, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer. 2002;98:737–40.CrossRefPubMed
12.
go back to reference Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431–57.CrossRefPubMed Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431–57.CrossRefPubMed
13.
go back to reference Singh AP, Senapati S, Ponnusamy MP, Jain M, Lele SM, Davis JS, et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 2008;9:1076–85.CrossRefPubMed Singh AP, Senapati S, Ponnusamy MP, Jain M, Lele SM, Davis JS, et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 2008;9:1076–85.CrossRefPubMed
14.
go back to reference Imai S, Haga S, Kiyozuka Y. Epitope characterization of MUC1 antibodies. Tumor Biol. 1998;19 suppl 1:30–4.CrossRef Imai S, Haga S, Kiyozuka Y. Epitope characterization of MUC1 antibodies. Tumor Biol. 1998;19 suppl 1:30–4.CrossRef
15.
go back to reference Schol DJ, Meulenbroek MFA, Snijdewint FGM, von Mensdorff-Pouilly S, Verstraeten RA, Murakami F, et al. “Epitope fingerprinting” using overlapping 20-mer peptides of the MUC1 tandem repeat sequence. Tumor Biol. 1998;19 suppl 1:35–45.CrossRef Schol DJ, Meulenbroek MFA, Snijdewint FGM, von Mensdorff-Pouilly S, Verstraeten RA, Murakami F, et al. “Epitope fingerprinting” using overlapping 20-mer peptides of the MUC1 tandem repeat sequence. Tumor Biol. 1998;19 suppl 1:35–45.CrossRef
16.
go back to reference Grinstead JS, Koganty RR, Krantz MJ, Longenecker BM, Campbell AP. Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide–antibody interactions. Biochem. 2002;41:9946–61.CrossRef Grinstead JS, Koganty RR, Krantz MJ, Longenecker BM, Campbell AP. Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide–antibody interactions. Biochem. 2002;41:9946–61.CrossRef
17.
go back to reference Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res. 1993;53:5386–94.PubMed Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res. 1993;53:5386–94.PubMed
18.
go back to reference Ferreira CSM, Matthews CS, Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumor Biol. 2006;27:289–301.CrossRef Ferreira CSM, Matthews CS, Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumor Biol. 2006;27:289–301.CrossRef
19.
go back to reference Warren DJ, Nustad K, Beard JB, O’Brien TJ. Expression and epitope characterization of a recombinant CA 125 repeat: fourth report from the ISOBM TD-1 workshop. Tumor Biol. 2009;30:51–60.CrossRef Warren DJ, Nustad K, Beard JB, O’Brien TJ. Expression and epitope characterization of a recombinant CA 125 repeat: fourth report from the ISOBM TD-1 workshop. Tumor Biol. 2009;30:51–60.CrossRef
20.
go back to reference Chan WC, White PD, editors. Fmoc solid phase peptide synthesis: a practical approach. New York: Oxford University Press; 2000. Chan WC, White PD, editors. Fmoc solid phase peptide synthesis: a practical approach. New York: Oxford University Press; 2000.
21.
go back to reference Diem M. Introduction to modern vibrational spectroscopy. New York: John Wiley and Sons; 1993. Diem M. Introduction to modern vibrational spectroscopy. New York: John Wiley and Sons; 1993.
22.
23.
go back to reference Maeda T, Inoue M, Koshiba S, Yabuki T, Aoki M, Nunokawa E, et al. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). J Biol Chem. 2004;279:13174–82.CrossRefPubMed Maeda T, Inoue M, Koshiba S, Yabuki T, Aoki M, Nunokawa E, et al. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). J Biol Chem. 2004;279:13174–82.CrossRefPubMed
24.
go back to reference Gubbels JAA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high-affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5:50.CrossRefPubMed Gubbels JAA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high-affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5:50.CrossRefPubMed
25.
go back to reference Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, et al. A binding domain on mesothelein for CA125/MUC16. J Biol Chem. 2009;284:3739–49.CrossRefPubMed Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, et al. A binding domain on mesothelein for CA125/MUC16. J Biol Chem. 2009;284:3739–49.CrossRefPubMed
26.
go back to reference Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007;67:4924–32.CrossRefPubMed Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007;67:4924–32.CrossRefPubMed
Metadata
Title
Synthesis and structural characterization of the peptide epitope of the ovarian cancer biomarker CA125 (MUC16)
Authors
Zach T. Berman
Lee J. Moore
Kathleen E. Knudson
Rebecca J. Whelan
Publication date
01-10-2010
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2010
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0062-4

Other articles of this Issue 5/2010

Tumor Biology 5/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine